22064 Federal Register / Vol. 61, No. 93 / Monday, May 13, 1996 / Notices

C. Investigations Policy and

Oversight.

Section AFJ.20, Office of

Investigations—Functions

A. Immediate Office of the Deputy

Inspector General for Investigations.

This office is directed by the Deputy

Inspector General for Investigations who

is responsible for the functions

designated in the law for the position,

Assistant Inspector General for

Investigations. The Deputy Inspector

General for Investigations supervises the

Assistant Inspectors General who head

the OI offices described below.

The Deputy Inspector General for

Investigations is responsible to the

Inspector General for carrying out the

investigative mission of the OIG and for

leading and providing general

supervision to the OIG investigative

component. The Immediate Office

coordinates quality assurance studies to

ensure that applicable laws, regulations,

policies, procedures, standards and

other requirements are followed in all

investigative activities performed by, or

on behalf of, the Department.

B. Criminal Investigations. This office

is directed by the Assistant Inspector

General for Criminal Investigations who

supervises a headquarters policy and

review staff and the Regional Inspectors

General for Investigations who carry out

investigative activities in their assigned

geographic areas.

1. The headquarters staff assists the

Deputy Inspector General for

Investigations to establish investigative

priorities, to evaluate the progress of

investigations, and to report to the

Inspector General on the effectiveness of

investigative efforts. It develops and

implements investigative techniques,

programs, guidelines and policies. It

provides programmatic expertise and

issues information on new programs,

procedures, regulations and statutes. It

directs and coordinates the investigative

field offices.

2. The headquarters staff reviews

completed reports of investigations to

ensure accuracy and compliance with

guidelines. It issues the reports to

pertinent agencies, management

officials and the Secretary and

recommends appropriate debarment

actions, administrative sanctions, CMPs

and other civil actions, or prosecution

under criminal law. It identifies

systemic and programmatic

vulnerabilities in the Department’s

operations and makes recommendations

for change to the appropriate managers.

3. The staff provides for the personal

protection of the Secretary.

4. The field offices conduct

investigations of allegations of fraud,

waste, abuse, mismanagement and

violations of standards of conduct and

other investigative matters within the

jurisdiction of the OIG. They coordinate

investigations and confer with HHS

operating divisions, staff divisions, OIG

counterparts and other investigative and

law enforcement agencies. They prepare

investigative and management

improvement reports.

C. Investigations Policy and Oversight.

This office is directed by the Assistant

Inspector General for Investigations

Policy and Oversight who leads

outreach activities to State and local

investigative agencies, and the general

management functions of the Office of

Investigations.

1. The office oversees State Medicaid

fraud control units and is responsible

for certifying and recertifying these

units and for auditing their Federal

funding. The office provides pertinent

information from HHS records to assist

Federal, State and local investigative

agencies to detect, investigate and

prosecute fraud. It manages the HHS

Hotline to receive complaints and

allegations of fraud, waste and abuse,

and to refer the information for

investigation, audit, program review, or

other appropriate action. It coordinates

with the GAO hotline and hotlines from

other agencies.

2. The office maintains an automated

data and management information

system used by all OI managers and

investigators. It provides technical

expertise on computer applications for

investigations and coordinates and

approves investigative computer

matches with other agencies.

3. The office develops general

management policy for the OI. It

develops and issues instructional media

on detecting wrongdoing and on

investigating and processing cases. The

office reviews proposed legislation,

regulations, policies and procedures to

identify vulnerabilities and

recommends modification where

appropriate. It reviews investigative

files in response to Privacy and

Freedom of Information Act requests. It

plans, develops, implements and

evaluates all levels of employee training

for investigations, management, support

skills and other functions, and serves as

OIG liaison to the Office of the Secretary

for Freedom of Information and Privacy

Act requests. It coordinates general

management processes, e.g., compiles

reports on the budget, on awards and on

other personnel matters for OI as a

whole; implements policies and

procedures published in the OIG

Administrative Manual; and processes

procurement requests and other service

related actions.

Dated: April 25, 1996.

June Gibbs Brown,

Inspector General.

[FR Doc. 96–11844 Filed 5–10–96; 8:45 am]

BILLING CODE 4150–04–P

Centers for Disease Control and

Prevention

Clinical Laboratory Improvement

Advisory Committee (CLIAC): Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following committee

meeting.

Name: Clinical Laboratory Improvement

Advisory Committee.

Times and Dates: 1–5 p.m., May 29, 1996;

8 a.m.–4 p.m., May 30, 1996.

Place: CDC, Auditorium B, Building 2,

1600 Clifton Road, NE., Atlanta, Georgia

30333.

Status: Open to the public, limited only by

the space available.

Purpose: This committee is charged with

providing scientific and technical advice and

guidance to the Secretary of Health and

Human Services, the Assistant Secretary for

Health, and the Director, CDC, regarding the

need for, and the nature of, revisions to the

standards under which clinical laboratories

are regulated; the impact of proposed

revisions to the standards; and the

modification of the standards to

accommodate technological advances.

Matters To Be Discussed: Agenda items

include: An update on the Clinical

Laboratory Improvement Amendments

(CLIA), review of CLIA quality control issues

discussed at the August 30–31, 1995, CLIAC

meeting; and proposals for addressing these

issues.

Agenda items are subject to change as

priorities dictate.

Contact Person for Additional Information:

John C. Ridderhof, Dr. P.H., Division of

Laboratory Systems, Public Health Practice

Program Office, CDC, 4770 Buford Highway,

NE., M/S G–25, Atlanta, Georgia 30341–3724,

telephone 404/488–7660.

Dated: May 2, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 96–11858 Filed 5–10–96; 8:45 am]

BILLING CODE 4163–18–M

Injury Research Grant Review

Committee: Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following committee

meeting.
Federal Register / Vol. 61, No. 93 / Monday, May 13, 1996 / Notices 22065

Name: Injury Research Grant Review

Committee (IRGRC).

Times and Dates: 6 p.m.–9 p.m., June 9,

1996; 8 a.m.–6 p.m., June 10, 1996.

Place: The Palmer House Hilton, 17 East

Monroe Street, Chicago, Illinois 60603–5605.

Status: Open: 6 p.m.–7 p.m., June 9, 1996;

Closed: 7 p.m.–9 p.m., June 9, 1996; Closed:

8 a.m.–6 p.m., June 10, 1996.

Purpose: This committee is charged with

advising the Secretary of Health and Human

Services, the Assistant Secretary for Health,

and the Director, CDC, regarding the

scientific merit and technical feasibility of

grant applications received from academic

institutions and other public and private

profit and nonprofit organizations, including

State and local government agencies, to

conduct specific injury research that focus on

prevention and control and to support injury

prevention research centers.

Matters To Be Discussed: Agenda items

include: announcements, discussion of

review procedures, future meeting dates, and

review of grant applications.

Beginning at 7 p.m., June 9, through 6 p.m.,

June 10, the Committee will meet to conduct

a review of grant applications. This portion

of the meeting will be closed to the public

in accordance with provisions set forth in

section 552b(c) (4) and (6), title 5 U.S.C., and

the Determination of the Associate Director

for Management and Operations, CDC,

pursuant to Pub. L. 92–463.

Agenda items are subject to change as

priorities dictate.

Contact Person for More Information:

Richard W. Sattin, M.D., Executive Secretary,

IRGRC, National Center for Injury Prevention

and Control, CDC, 4770 Buford Highway,

NE., M/S K58, Atlanta, Georgia 30341–3724,

telephone 770/488–4580.

Dated: May 3, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services

Office Centers for Disease Control and

Prevention (CDC).

[FR Doc. 96–11857 Filed 5–10–96; 8:45 am]

BILLING CODE 4163–18–M

Health Resources and Services

Administration

Advisory Commission on Childhood

Vaccines; Request for Nominations for

Voting Members

AGENCY: Health Resources and Services

Administration.

ACTION: Notice.

SUMMARY: The Health Resources and

Services Administration (HRSA) is

requesting nominations to fill three

vacancies on the Advisory Commission

on Childhood Vaccines (ACCV). The

ACCV was established by title XXI of

the Public Health Service Act (the Act),

as enacted by Public Law (P.L.) 99–660

and as subsequently amended, and

advises the Secretary of Health and

Human Services (the Secretary) on

issues related to implementation of the

National Vaccine Injury Compensation

Program (VICP).

FOR FURTHER INFORMATION CONTACT: Ms.

Melissa Palmer, Committee

Management Assistant, Policy and

Commission Branch, Division of

Vaccine Injury Compensation, at (301)

443–1533.

DATES: Nominations are to be submitted

by June 13, 1996.

ADDRESSES: All nominations are to be

submitted to the Director, Division of

Vaccine Injury Compensation, Bureau of

Health Professions, HRSA, Parklawn

Building, Room 8A–35, 5600 Fishers

Lane, Rockville, Maryland 20857.

SUPPLEMENTARY INFORMATION: Under the

authorities that established the ACCV,

viz., the Federal Advisory Committee

Act of October 6, 1972 (P.L. 92–463) and

section 2119 of the Act, 42 U.S.C. 300aa19, as added by P.L. 99–660 and

amended, HRSA is requesting

nominations for three voting members

of the ACCV.

The ACCV advises the Secretary on

the implementation of the VICP; on its

own initiative or as the result of the

filing of a petition, recommends changes

in the Vaccine Injury Table; advises the

Secretary in implementing the

Secretary’s responsibilities under

section 2127 regarding the need for

childhood vaccination products that

result in fewer or no significant adverse

reactions; surveys Federal, State, and

local programs and activities relating to

the gathering of information on injuries

associated with the administration of

childhood vaccines, including the

adverse reaction reporting requirements

of section 2125(b); advises the Secretary

on means to obtain, compile, publish,

and use credible data related to the

frequency and severity of adverse

reactions associated with childhood

vaccines; and recommends to the

Director, National Vaccine Program,

research related to vaccine injuries

which should be conducted to carry out

the VICP.

The ACCV consists of nine voting

members appointed by the Secretary as

follows: three health professionals, of

whom at least two are pediatricians,

who are not employees of the United

States, who have expertise in the health

care of children, the epidemiology,

etiology and prevention of childhood

diseases, and the adverse reactions

associated with vaccines; three members

from the general public, of whom at

least two are legal representatives

(parents or guardians) of children who

have suffered a vaccine-related injury or

death; and three attorneys, of whom at

least one shall be an attorney whose

specialty includes representation of

persons who have suffered a vaccinerelated injury or death and one shall be

an attorney whose specialty includes

representation of vaccine

manufacturers. In addition, the Director

of the National Institutes of Health, the

Assistant Secretary for Health, the

Director of the Centers for Disease

Control and Prevention, and the

Commissioner of the Food and Drug

Administration (or the designees of such

officials) serve as nonvoting ex officio

members.

Specifically, HRSA is requesting

nominations for three voting members

of the ACCV representing: (1) A health

professional with special experience in

childhood diseases; (2) a member from

the general public who is a legal

representative (parent or guardian) of a

child who has suffered a vaccine-related

injury or death; and (3) an attorney with

no specific affiliation (as stated above,

this category requires membership of

three attorneys, of whom at least one

shall be an attorney whose specialty

includes representation of persons who

have suffered a vaccine-related injury or

death and one of whom is an attorney

whose specialty includes representation

of vaccine manufacturers—by this

notice, the Department is soliciting

nominations for the third attorney

position). Nominees will be invited to

serve 3-year terms beginning January 1,

1997, and ending December 31, 1999.

Interested persons may nominate one

or more qualified persons for

membership on the ACCV. Nominations

shall state that the nominee is willing to

serve as a member of the ACCV and

appears to have no conflict of interest

that would preclude the ACCV

membership. Potential candidates will

be asked to provide detailed information

concerning such matters as financial

holdings, consultancies, and research

grants or contracts to permit evaluation

of possible sources of conflicts of

interest. A curriculum vitae should be

submitted with the nomination.

The Department of Health and Human

Services has special interest in assuring

that women, minority groups, and the

physically handicapped are adequately

represented on advisory committees and

therefore extends particular

encouragement to nominations for

appropriately qualified female,

minority, or physically handicapped

candidates.

Dated: May 7, 1996.

Ciro V. Sumaya,

Administrator.

[FR Doc. 96–11878 Filed 5–10–96; 8:45 am]

BILLING CODE 4160–15–P